The Short Version

Calcitonin gene-related peptide, or CGRP, is the signaling molecule at the center of the biggest shift in migraine treatment in a generation. It is the target of the gepants and the anti-CGRP antibodies. So it is reasonable to wonder: if CGRP drives migraine, could a simple blood test for CGRP tell you how active your migraine is, or even predict who will respond to treatment?

A new study in Neurology, drawing on a large migraine registry, set out to answer exactly that. The researchers measured plasma CGRP in 588 people with migraine and 147 carefully matched healthy controls. The headline finding was a surprise. Plasma CGRP was not higher in people with migraine. It was modestly lower. And it did not track with migraine type, whether someone was in an attack or between attacks, or whether they were on preventive treatment.

A Quick CGRP Refresher

CGRP is a small messenger molecule released by sensory nerves, including the trigeminal nerves that wrap around the blood vessels and coverings of the brain. When those nerves fire during a migraine attack, they release CGRP, which widens blood vessels, drives inflammation around them, and turns up pain signaling. That is why blocking CGRP, or the receptor it docks onto, can prevent attacks or stop one in progress.

The evidence that CGRP is genuinely involved in migraine is strong and comes from decades of work. CGRP levels rise in blood drawn from the jugular vein during attacks. Infusing CGRP into a vein can reproduce a migraine-like attack in many people who live with the condition. And drugs designed to block CGRP reliably reduce attacks. None of that is in question here.

What the Study Did

According to PubMed, this was a cross-sectional observational study built on a large migraine registry. Adults with migraine with aura, migraine without aura, or chronic migraine were enrolled, mostly from specialized headache care. Healthy controls with no personal or first-degree family history of a primary headache disorder were recruited mainly through online advertising.

Blood was drawn from a vein in the arm, and plasma CGRP was measured twice per sample using a validated, high-affinity radioimmunoassay. Controls were matched to participants with migraine at a ratio of four people with migraine to each control, balanced for age, sex, body mass index, and how long the sample had been in storage. The main question was simply whether plasma CGRP differed between the two groups, and whether it varied with migraine subtype, attack status, or preventive medication use.

What They Found

Plasma CGRP was modestly lower in people with migraine than in controls. The median value was 125 pmol/L in the migraine group versus 151 pmol/L in controls, a difference that was statistically significant. Just as important as the direction was what did not change. Levels did not differ meaningfully between episodic and chronic migraine, between migraine with and without aura, or between people who were in an attack and those who were between attacks. Preventive medication use did not move the numbers either.

The researchers also ran sensitivity analyses restricted to people who were headache-free at the time of the blood draw, and the pattern held: CGRP was lower across all migraine subgroups. They could not find any clinical feature that predicted a person's plasma CGRP level, and how long a sample had been stored did not explain the results. In other words, the lower level in migraine was consistent, but it was flat and uninformative across everything clinicians actually care about.

Blood CGRP and Brain CGRP Are Not the Same Thing

This is the part that resolves the apparent paradox, and it is worth sitting with. A migraine attack is driven by CGRP released locally, from trigeminal nerve endings around the blood vessels and meninges of the head. That is a focused, short-lived burst in a specific place. A blood sample taken from a vein in the arm measures the resting level of CGRP circulating through the whole body, which is shaped by many tissues and processes that have nothing to do with a headache.

So a low or unremarkable level in arm blood does not contradict the idea that CGRP floods the trigeminal system during an attack. The two measurements are looking at different things. The earlier studies that found CGRP rising during attacks sampled blood from the jugular vein, which drains the head, and timed it to the attack itself. A one-time peripheral draw is a much blurrier window, and this study suggests it is too blurry to be useful as a migraine readout.

Does This Change Anything About the CGRP Drugs?

No, and this is the most important point to be clear about. The gepants and the anti-CGRP antibodies work by blocking CGRP or its receptor at the trigeminal system, where the action happens during an attack. Their effectiveness was established in large randomized trials measured by whether they reduce migraine attacks, not by what they do to a resting blood level. This study does not weaken that evidence in any way.

What the study does push back on is a narrower hope: that a routine blood CGRP test might be used to diagnose migraine, gauge its severity, or predict who will respond to a CGRP-targeted drug. Based on these results, resting plasma CGRP is not a good candidate for any of those jobs. If anything, the finding is a useful caution against over-interpreting a number from a simple blood draw.

"CGRP is clearly central to migraine, but that does not mean its level in a routine blood sample tells you what your migraine is doing. The molecule matters. This particular measurement of it does not appear to." - Cerebral Torque

Why CGRP Is So Hard to Measure

Part of the backstory here is that CGRP has always been a difficult molecule to pin down in blood. It is cleared quickly, so its level can swing over short windows. Different laboratories have used different assays over the years, and those assays do not always agree, which is one reason earlier reports on blood CGRP in migraine have been inconsistent. A strength of this study is that it used a single validated assay across a large, well-characterized group, with controls matched even on how long samples sat in storage.

That methodological care is exactly why the flat, uninformative result is worth taking seriously. This was not a small or sloppy study that failed to find a signal. It was a large and careful one that looked hard and concluded the signal is not there in peripheral blood, at least not in a form clinicians could use.

What It Means For You

Limitations Worth Knowing

This was a cross-sectional study, meaning it captured a single snapshot in time rather than following people across many attacks, so it cannot speak to how CGRP might move within an individual over a longer arc. The people with migraine were recruited largely from specialized headache clinics, while controls came mainly from online advertising, and those groups can differ in ways beyond migraine. The study measured peripheral plasma specifically, so it does not address CGRP in the cerebrospinal fluid, tear fluid, saliva, or jugular blood, which other researchers continue to explore. As always, an observed difference between groups is an association, not proof of cause, and the modestly lower level in migraine does not by itself explain anything mechanistically.

Conclusions

A large, carefully conducted study found that resting plasma CGRP is modestly lower, not higher, in people with migraine, and that it does not vary with the things clinicians care about: migraine type, attack status, or treatment. The most useful way to read this is not as a challenge to CGRP's role in migraine, which is well established, but as a clear answer to a practical question. A peripheral blood CGRP test does not look like a viable biomarker for migraine. The molecule is still central. This particular way of measuring it is not the window into the disease that many had hoped for.